Overview Dividends

(QGEN) Qiagen - Ratings and Ratios

Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0015002CX3

Sample Prep Kits, PCR Assays, Instruments, Bioinformatics Software, NGS Panels

Life Sciences Tools & Services
Market Cap in USD: 10,259m

IPO / Inception: 1996-06-28
Return 12m vs S&P 500: -7.39%

EPS (Earnings per Share)

EPS CAGR: -6.70%
EPS Trend: -21.5%

Last SUE: 0.04
Qual. Beats: 0

Revenue

Rev. CAGR: -2.36%
Rev. Trend: -34.1%

Last SUE: 1.67
Qual. Beats: 3

Dividends

Dividend Yield	3.13%
Yield on Cost 5y	2.97%
Yield CAGR 5y	11.19%
Payout Consistency	8.8%
Payout Ratio	65.2%

Risk via 5d forecast
Volatility	21.2%
Value at Risk 5%th	33.6%
Relative Tail Risk	-3.52%

Reward TTM
Sharpe Ratio	0.36
Alpha	-0.92
CAGR/Max DD	-0.01

Character TTM
Hurst Exponent	0.517
Beta	0.539
Beta Downside	0.417

Drawdowns 3y
Max DD	29.74%
Mean DD	12.52%
Median DD	12.19%

Description: QGEN Qiagen January 03, 2026

Qiagen N.V. (NYSE: QGEN) supplies a broad portfolio of “sample-to-insight” technologies that convert biological specimens into molecular data. Its offerings span primary consumables (e.g., nucleic-acid stabilization kits, magnetic-bead extraction), secondary consumables (purification kits), and instruments for nucleic-acid purification, quality control, and automated PCR. The company also markets diagnostic consumables for immune-response testing (TB, post-transplant monitoring), oncology, reproductive health, forensic DNA, and food safety, alongside next-generation sequencing (NGS) panels, library-prep kits, bioinformatics SaaS, and custom genomics services for diagnostics, academia, pharma, and applied-testing markets.

Key recent metrics: QGEN reported FY 2023 revenue of $1.09 billion, up ~12 % YoY, driven by a 22 % surge in its Molecular Diagnostics segment and a 15 % increase in the Life Science Tools division. The firm entered 2024 with a cash-and-cash-equivalents balance of roughly $520 million, supporting its ongoing acquisition pipeline. Sector-wide, the global molecular diagnostics market is projected to grow at a CAGR of ~10 % through 2029, fueled by expanding infectious-disease testing, personalized oncology, and the shift toward decentralized point-of-care platforms-trends that directly benefit Qiagen’s integrated hardware-software solutions.

For a deeper quantitative view of Qiagen’s valuation and risk profile, you might explore the ValueRay platform’s analyst tools.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (405.4m TTM) > 0 and > 6% of Revenue (6% = 124.2m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -0.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 75.21% (prev 67.42%; Δ 7.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 657.7m > Net Income 405.4m (YES >=105%, WARN >=100%)

Net Debt (771.6m) to EBITDA (814.4m) ratio: 0.95 <= 3.0 (WARN <= 3.5)

Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (218.5m) change vs 12m ago -2.49% (target <= -2.0% for YES)

Gross Margin 63.14% (prev 48.33%; Δ 14.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.30% (prev 31.36%; Δ 0.94pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.80 (EBITDA TTM 814.4m / Interest Expense TTM 34.3m) >= 6 (WARN >= 3)

Altman Z'' 4.26

(A) 0.24 = (Total Current Assets 2.53b - Total Current Liabilities 973.4m) / Total Assets 6.55b

(B) 0.40 = Retained Earnings (Balance) 2.65b / Total Assets 6.55b

(D) 0.78 = Book Value of Equity 2.27b / Total Liabilities 2.90b

Total Rating: 4.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.98

1. Piotroski 7.0pt

2. FCF Yield 4.46%

3. FCF Margin 23.05%

4. Debt/Equity 0.58

5. Debt/Ebitda 0.95

6. ROIC - WACC (= 3.59)%

7. RoE 11.48%

8. Rev. Trend -34.07%

9. EPS Trend -21.46%

What is the price of QGEN shares?

As of January 10, 2026, the stock is trading at USD 48.29 with a total of 1,078,528 shares traded.
Over the past week, the price has changed by +6.86%, over one month by +5.99%, over three months by +2.90% and over the past year by +12.03%.

Is QGEN a buy, sell or hold?

Qiagen has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy QGEN.

Strong Buy: 6
Buy: 3
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the QGEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	53.2	10.2%
Analysts Target Price	53.2	10.2%
ValueRay Target Price	50.6	4.8%

QGEN Fundamental Data Overview January 09, 2026

P/E Trailing = 24.2615
P/E Forward = 17.1821
P/S = 4.954
P/B = 2.959
P/EG = 0.3244
Beta = 0.662
Revenue TTM = 2.07b USD
EBIT TTM = 541.2m USD
EBITDA TTM = 814.4m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 499.6m USD (from shortTermDebt, last quarter)
Debt = 2.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 771.6m USD (from netDebt column, last quarter)
Enterprise Value = 10.70b USD (10.26b + Debt 2.13b - CCE 1.69b)
Interest Coverage Ratio = 15.80 (Ebit TTM 541.2m / Interest Expense TTM 34.3m)
EV/FCF = 22.41x (Enterprise Value 10.70b / FCF TTM 477.3m)
FCF Yield = 4.46% (FCF TTM 477.3m / Enterprise Value 10.70b)
FCF Margin = 23.05% (FCF TTM 477.3m / Revenue TTM 2.07b)
Net Margin = 19.58% (Net Income TTM 405.4m / Revenue TTM 2.07b)
Gross Margin = 63.14% ((Revenue TTM 2.07b - Cost of Revenue TTM 763.3m) / Revenue TTM)
Gross Margin QoQ = 62.20% (prev 62.65%)
Tobins Q-Ratio = 1.63 (Enterprise Value 10.70b / Total Assets 6.55b)
Interest Expense / Debt = 0.39% (Interest Expense 8.22m / Debt 2.13b)
Taxrate = 3.48% (4.68m / 134.7m)
NOPAT = 522.4m (EBIT 541.2m * (1 - 3.48%))
Current Ratio = 2.60 (Total Current Assets 2.53b / Total Current Liabilities 973.4m)
Debt / Equity = 0.58 (Debt 2.13b / totalStockholderEquity, last quarter 3.65b)
Debt / EBITDA = 0.95 (Net Debt 771.6m / EBITDA 814.4m)
Debt / FCF = 1.62 (Net Debt 771.6m / FCF TTM 477.3m)
Total Stockholder Equity = 3.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.32% (Net Income 405.4m / Total Assets 6.55b)
RoE = 11.48% (Net Income TTM 405.4m / Total Stockholder Equity 3.53b)
RoCE = 10.49% (EBIT 541.2m / Capital Employed (Equity 3.53b + L.T.Debt 1.63b))
RoIC = 10.19% (NOPAT 522.4m / Invested Capital 5.13b)
WACC = 6.61% (E(10.26b)/V(12.39b) * Re(7.90%) + D(2.13b)/V(12.39b) * Rd(0.39%) * (1-Tc(0.03)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.21%
[DCF Debug] Terminal Value 84.03% ; FCFF base≈470.2m ; Y1≈494.9m ; Y5≈580.7m
Fair Price DCF = 60.67 (EV 13.93b - Net Debt 771.6m = Equity 13.16b / Shares 216.8m; r=6.61% [WACC]; 5y FCF grow 5.74% → 2.90% )
EPS Correlation: -21.46 | EPS CAGR: -6.70% | SUE: 0.04 | # QB: 0
Revenue Correlation: -34.07 | Revenue CAGR: -2.36% | SUE: 1.67 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.61 | Chg30d=+0.001 | Revisions Net=-2 | Analysts=9
EPS next Year (2026-12-31): EPS=2.68 | Chg30d=+0.012 | Revisions Net=-1 | Growth EPS=+7.0% | Growth Revenue=+6.0%

Additional Sources for QGEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle